Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Apr 18, 2019

Nemolizumab Shows Positive Results in Maruho’s Phase 3 Study in Atopic Dermatitis

TOKYO, April 18, 2019 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Maruho Co., Ltd. reported results from a phase 3 study investigating the efficacy and safety of nemolizumab (CIM331) with atopic dermatitis patients 13 years of age or older who had moderate-to-severe pruritus. Nemolizuab was created by Chugai, and is currently under development in Japan by Maruho for atopic dermatitis.

Press release by Maruho issued on April 18, 2019:
Maruho Announces Positive Phase 3 Results of Nemolizumab in Patients with Atopic Dermatitis

Press release issued on September 28, 2016:
Chugai and Maruho Announce License Agreement of Nemolizumab (CIM331), a Novel Biologic in the Skin Disease Area for the Japanese Market


  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail:
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail:
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top